National Institutes of Health

US Declines to Force Lower Price on Cancer Drug Xtandi

The U.S. government will not force Pfizer Inc and Astellas Pharma Inc to lower the price of their prostate cancer drug Xtandi using its emergency “march-in” authority, the National Institutes of Health (NIH) said on Tuesday. March-in rights, which have never been used before, allow the government to grant additional licenses to third parties for […]